December 17, 2025
Headlines

BioScience

LTZ Therapeutics Secures $20M Series A to Revolutionize Cancer Treatment with Cutting-Edge Myeloid Engager Technology

Editor04 mins

LTZ Therapeutics, an emerging leader in immunotherapy, has successfully completed a $20 million Series A financing round. This round, spearheaded by new investor Lapam Capital and including significant contributions from GL Ventures, K2 Venture Partners, and Shunwei Capital, brings LTZ’s total funding to approximately $50 million since its inception in 2022. The new capital will…

Read More

Biophyle Unveils Groundbreaking Accelerator Program for Clinical-Stage Biotech Innovations and Local Research Training

Editor06 mins

In a major boost to healthcare innovation, SymBiosis and HealthTech Arkansas have announced the launch of the biophyle Trial Accelerator, a pioneering initiative aimed at bridging the gap between cutting-edge clinical-stage biotherapeutics and Arkansas’ healthcare ecosystem. This strategic program is designed to catalyze the commercialization of novel treatments by connecting biotherapeutic innovations with clinical trial…

Read More

Ancilia Biosciences Secures $4.2 Million in Financing to Advance CRISPR-Based Bacterial Therapies

Editor04 mins

Ancilia Biosciences, a pioneering biotechnology firm specializing in harnessing CRISPR technology for bacterial therapies, announced today the successful closure of an $4.2 million financing round. Safar Partners led the investment, joined by Metaplanet, Psymed Ventures, Zubi Capital, Spacecadet Ventures, and other institutional and private investors. The funding underscores the company’s commitment to leveraging CRISPR’s natural…

Read More

Predicta Biosciences Secures $5.2 Million Investment to Pave the Way in Blood Cancer Diagnostics

Editor05 mins

Predicta Biosciences, a pioneering precision oncology company, has announced a significant milestone with the successful closure of an oversubscribed $5.2 million seed funding round. Led by The Engine Ventures, this round saw participation from notable investors including Illumina Ventures, Time Boost Capital, the American Cancer Society Bright Edge, and the Oetgen family. The funds raised…

Read More

Element Biosciences Secures $277 Million to Propel Innovation in DNA Sequencing and Multi-Omics

Editor05 mins

Element Biosciences, a trailblazer in advancing scientific discovery through groundbreaking technologies, has announced a significant milestone in its journey of innovation. The company has successfully raised over $277 million in Series D funding, underscoring its pivotal role in revolutionizing DNA sequencing and multi-omics technologies. This latest round, led by Wellington Management and supported by a…

Read More